These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. Lee JH, Kim Y, Choi JW, Kim YS. J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323 [Abstract] [Full Text] [Related]
25. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. Kang HJ, Ryu MH, Kim KM, Park YS, Choi J, Ryoo BY, Kim WH, Im SA, Bang YJ, Park SH, Lee JH, Chung IJ, Bae HI, Kim JG, Lee KH, Song HS, Kwon HC, Baek JH, Shin DB, Lee KE, Kang YK. Acta Oncol; 2012 Apr; 51(4):528-36. PubMed ID: 22150077 [Abstract] [Full Text] [Related]
27. [Gastrointestinal stromal tumours in pediatrics: a summary of the literature on this orphan disease]. Verschuur A, André N, Blay JY. Bull Cancer; 2011 Jan; 98(1):79-86. PubMed ID: 21300610 [Abstract] [Full Text] [Related]
28. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors. Künstlinger H, Binot E, Merkelbach-Bruse S, Huss S, Wardelmann E, Buettner R, Schildhaus HU. Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465 [Abstract] [Full Text] [Related]
30. Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors. Daum O, Grossmann P, Vanecek T, Sima R, Mukensnabl P, Michal M. Ann Diagn Pathol; 2007 Feb; 11(1):27-33. PubMed ID: 17240304 [Abstract] [Full Text] [Related]
31. High expression of the RNA-binding protein RBPMS2 in gastrointestinal stromal tumors. Hapkova I, Skarda J, Rouleau C, Thys A, Notarnicola C, Janikova M, Bernex F, Rypka M, Vanderwinden JM, Faure S, Vesely J, de Santa Barbara P. Exp Mol Pathol; 2013 Apr; 94(2):314-21. PubMed ID: 23295309 [Abstract] [Full Text] [Related]
32. [GIST refractory to imatinib treatment]. Onozawa Y, Terashima M. Gan To Kagaku Ryoho; 2011 May; 38(5):738-43. PubMed ID: 21566433 [Abstract] [Full Text] [Related]
38. Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing. Künstlinger H, Huss S, Merkelbach-Bruse S, Binot E, Kleine MA, Loeser H, Mittler J, Hartmann W, Hohenberger P, Reichardt P, Büttner R, Wardelmann E, Schildhaus HU. Am J Surg Pathol; 2013 Nov 02; 37(11):1648-59. PubMed ID: 24061512 [Abstract] [Full Text] [Related]
39. Gastrointestinal stromal tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes. Blay JY, Le Cesne A, Cassier PA, Ray-Coquard IL. Discov Med; 2012 May 02; 13(72):357-67. PubMed ID: 22642917 [Abstract] [Full Text] [Related]
40. Multiple gastric stromal tumors in a child without syndromic association lacks common KIT or PDGFRalpha mutations. O'Sullivan MJ, McCabe A, Gillett P, Penman ID, MacKinlay GA, Pritchard J. Pediatr Dev Pathol; 2005 May 02; 8(6):685-9. PubMed ID: 16328663 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]